A Perspective of Immunotherapy for Prostate Cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2016-07-07 / Cancers (Basel) 2016 Jul;8(7)Recent advances in immuno-oncology and its application to urological cancers
/in Dendritic Cells, Hypernephroma, International Publications, Newcastle Disease Virus, Prostate Cancer, Urothelial Carcinoma /von 2016-06-03 / BJU Int. 2016 10;118(4):506-14Oncolytic virotherapy for urological cancers
/in International Publications, Newcastle Disease Virus, Prostate Cancer /von 2016-05-24 / Nat Rev Urol 2016 Jun;13(6):334-52Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma
/in Dendritic Cells, Glioblastoma, Immunogenic Cell Death, International Publications, Prostate Cancer /von 2016-03-02 / Sci Transl Med 2016 Mar;8(328):328ra27Autologous dendritic cell vaccination (DCVAC/PCa) added to docetaxel chemotherapy in a double-blind, randomized phase III trial (VIABLE) in men with advanced (mCRPC) prostate cancer.
/in Dendritic Cells, International Publications, Prostate Cancer /von 2015-05-30 / J Clin Oncol 33, 2015 (suppl; abstr TPS5070)Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate Cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2015-03-17 / Biol. Pharm. Bull. 2015;38(6):827-35A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment
/in Dendritic Cells, International Publications, Prostate Cancer /von 2015-01-29 / Oncol. Rep. 2015 Apr;33(4):1585-92Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms
/in Dendritic Cells, International Publications, Prostate Cancer /von 2015-01-07 / Urol. Oncol. 2015 May;33(5):245-60Long-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report
/in Dendritic Cells, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus, Prostate Cancer /von 2014-10-06 / Oncol Lett 2014 Dec;8(6):2403-2406
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de